Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)

Trial Profile

A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium fytate (Primary)
  • Indications Cardiovascular disorders; Vascular calcification
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CaLIPSO
  • Sponsors Laboratoris Sanifit
  • Most Recent Events

    • 11 Nov 2019 Results comparing progression of coronary artery calcium volume score and other measurements of cardiovascular calcification by CT scan during 52 weeks of treatment with SNF472 in adults patients with ESKD receiving hemodialysis published in the Circulation
    • 30 Oct 2019 According to a Sanifit media release, the top line results from this trial will be presented at the Featured Science Session of the 2019 Scientific Sessions of the American Heart Association (AHA) on 16 November 2019 in Philadelphia, Pennsylvania. The company will also host a conference call to discuss the data from this trial at 11am ET / 5pm CET / 4pm GMT on Monday 18 November.
    • 30 Oct 2019 Primary endpoint (The primary endpoint is the absolute change in coronary artery calcium volume scores measured by CT scan) has been met, according to the Sanifit media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top